AstraZeneca Wang Lei: Continue to increase investment in research and development and medical innovation in China
阿豆学长长ov
发表于 2023-11-5 17:09:09
261
0
0
Wang Lei, Global Executive Vice President and President of International Business and China at AstraZeneca, stated that over the past five years, relying on the advantages of China's large market, CIIE has made positive contributions to accelerating the construction of a new development pattern and promoting world economic development. Through the CIIE, AstraZeneca deeply felt the signal of China's adherence to opening-up and continued support for economic globalization, as well as its responsible image as a major country.
Wang Lei stated that AstraZeneca, as an old friend of CIIE, has participated in six consecutive exhibitions this year. Relying on the strong influence and spillover effects of the CIIE platform, AstraZeneca will announce the latest progress in investment in China at this CIIE, continue to increase investment in China, including research and development, medical innovation, and promote production and supply layout. AstraZeneca will also work with cross-border partners to continuously assist Chinese enterprises and innovative achievements in accelerating their "going global" journey, creating a "global new" with "China's new" approach, promoting the sustainable development of healthcare and contributing to the cause of human health.
Wang Lei stated that history has proven that the Chinese economy is a very stable development ship, and China is one of the largest markets in the world. AstraZeneca will use a more determined belief to play a role as a link and bridge, deepening its long-term commitment to "rooted in China, serving China, and benefiting the world".
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
You may like
- The big news of "weight loss miracle drug"! Oral Smegglutide Approved for Market in China
- Industry shock! Alibaba Cloud suddenly announced the largest price reduction in history!
- Continuously focusing on content and increasing AI investment in iQiyi's current year
- Novo Nordisk's new weight loss oral medication is applying for clinical efficacy or surpassing smeglutide in China
- How effective is the drug supply process initiated by Novo Nordisk for the approved slimming version of Smegglutide in China?
- "Weight loss pills" are sold in limited quantities in China? Novo Nordisk's latest response
- Yizi International expands its business in China and adds equity investment in Enxi Village
- Yizi International further expands its business in China and significantly increases its equity investment in Enxi Village
- Yizi International further expands its business in China and significantly increases its equity investment in Enxi Village
- China International Import Expo opens listening mode, 'all students' look forward to the prospects of the Chinese market
-
11월 14일, 세계예선 아시아지역 제3단계 C조 제5라운드, 중국남자축구는 바레인남자축구와 원정경기를 가졌다.축구 국가대표팀은 바레인을 1-0으로 꺾고 예선 2연승을 거두었다. 특히 이번 경기 국내 유일한 중계 ...
- 我是来围观的逊
- 15 분전
- Up
- Down
- Reply
- Favorite
-
"영비릉: 2024회계연도 영업수입 동기대비 8% 감소"영비릉은 2024회계연도 재무제보를 발표했다.2024 회계연도 매출은 149억5500만 유로로 전년 동기 대비 8% 감소했습니다.이익은 31억 500만 유로입니다.이익률은 ...
- 勇敢的树袋熊1
- 3 일전
- Up
- Down
- Reply
- Favorite
-
계면신문기자 장우발 4분기의 영업수입이 하락한후 텐센트음악은 다시 성장으로 돌아왔다. 11월 12일, 텐센트음악은 최신 재보를 발표했다.2024년 9월 30일까지 이 회사의 3분기 총수입은 70억 2천만 위안으로 전년 ...
- 勇敢的树袋熊1
- 그저께 15:27
- Up
- Down
- Reply
- Favorite
-
본사소식 (기자 원전새): 11월 14일, 다다그룹 (나스닥코드: DADA) 은 2024년 3분기 실적보고를 발표했다. 수치가 보여준데 따르면 고품질발전전략에 지속적으로 전념하고 사용자체험을 끊임없이 최적화하며 공급을 ...
- 家养宠物繁殖
- 어제 15:21
- Up
- Down
- Reply
- Favorite